Please assess the completion status of the following clinical trial:

Trial Title: EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 6 months to \< 6 years who have been treated for at least 2 months or, in case of catheter related thrombosis, for at least 6 weeks with LMWH (low molecular weight heparin), fondaparinux and/or VKA (vitamin K antagonist) for documented symptomatic or asymptomatic venous thrombosis - Hemoglobin, platelets, creatinine, alanine aminotransferase (ALT) and bilirubin evaluated within 10 days prior to randomization~* Informed consent provided~Exclusion Criteria:~* Active bleeding or high risk for bleeding contraindicating anticoagulant therapy~* Symptomatic progression of venous thrombosis during preceding anticoagulant treatment~* Planned invasive procedures, including lumbar puncture and removal of non peripherally placed central lines during study treatment~* An estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m\^2~* Hepatic disease which is associated with either: coagulopathy leading to a clinically relevant bleeding risk, or ALT\> 5x upper level of normal (ULN) or total bilirubin \> 2x ULN with direct bilirubin \> 20% of the total~* Platelet count \< 50 x 10\*9/L~* Hypertension defined as \> 95th age percentile~* Life expectancy \< 3 months~* Concomitant use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 (CYP3A4) and P-glycoprotein (P-gp), i.e. all human immunodeficiency virus protease inhibitors and the following azole antimycotics agents: ketoconazole, itraconazole, voriconazole, posaconazole, if used systemically~* Concomitant use of strong inducers of CYP3A4, i.e. rifampicin, rifabutin, phenobarbital, phenytoin and carbamazepine~* Hypersensitivity or any other contraindication listed in the local labeling for the comparator treatment or experimental treatment~* Inability to cooperate with the study procedures~* Previous randomization to this study~* Participation in a study with an investigational drug or medical device within 30 days prior to randomization

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): Age and body weight-adjusted twice daily dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).